多发性肌炎/皮肌炎合并间质性肺病患者的血清基质金属蛋白酶水平
该回顾性研究分析了52例PM/DM-ILD患者血清中7种MMP的水平,并按抗体状态分组。结果显示抗ARS抗体阳性组血清MMP-7水平显著高于其他组;在抗MDA5抗体阳性组中,血清MMP-7>5.08 ng/ml与更差的总生存相关(单因素P=0.017,多因素P=0.027)。
要点
- 抗ARS抗体阳性PM/DM-ILD患者血清MMP-7水平显著升高
- 抗MDA5抗体阳性PM/DM-ILD患者中MMP-7>5.08 ng/ml提示预后更差
- MMP-7可能参与纤维化过程,表达于纤维化病灶邻近的II型肺泡上皮细胞
核心结论
- 血清MMP-7水平在抗ARS抗体阳性PM/DM-ILD患者中升高,而在抗MDA5抗体阳性患者中高MMP-7水平与更差预后相关。
- 纤维化过程可能与血清MMP-7水平升高有关。
研究设计与样本
- 患者根据抗ARS抗体、抗MDA5抗体或缺乏抗体分为ARS-ILD组、MDA5-ILD组和其他ILD组,并独立分析。
- 另分析18例无ILD的PM/DM患者和55例健康对照。
主要发现
- ARS-ILD组血清MMP-7水平显著高于其他PM/DM患者组或健康对照。
- MDA5-ILD组中,血清MMP-7>5.08 ng/ml与更差的总生存相关(单因素P=0.017,OR=18.0,95%CI 1.69-192.00;多因素P=0.027,OR=14.60,95%CI 1.11-192.00)。
- 免疫组化提示MMP-7表达于纤维化病灶邻近的II型肺泡上皮细胞。
关键数值与推荐
- 血清MMP-7阈值:>5.08 ng/ml(用于MDA5-ILD组预后分析)。
- 单因素分析:P=0.017,OR=18.0,95%CI 1.69-192.00。
- 多因素分析:P=0.027,OR=14.60,95%CI 1.11-192.00。
临床怎么用
- 在抗MDA5抗体阳性PM/DM-ILD患者中,检测血清MMP-7水平可能有助于预后分层。
- 血清MMP-7>5.08 ng/ml提示抗MDA5抗体阳性PM/DM-ILD患者预后更差。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We aimed to clarify the clinical significance of serum levels of MMPs in interstitial lung disease (ILD) complicated with PM/DM (PM/DM-ILD). METHODS: We retrospectively analysed serum levels of seven subsets of MMPs in 52 PM/DM-ILD patients diagnosed at Kyoto University Hospital or Tenri Hospital from January 2005 to December 2014. The patients were sub-grouped based on the presence of anti-amimoacyl-tRNA synthetase antibody (anti-ARS antibody), anti-melanoma differentiation-associated protein 5 antibody (anti-MDA5 antibody) or lack of the antibodies (ARS-ILD, MDA5-ILD and other-ILD groups, respectively) and independently analysed. Eighteen PM/DM patients without ILD and 55 healthy control were also analysed. Associations between serum levels of MMPs and clinical findings including mortality were analysed. RESULTS: Among the MMPs analysed, MMP-7 serum levels in the ARS-ILD group were significantly higher compared with those in any of the other groups of PM/DM patients or in healthy controls. On the other hand, in the MDA5-ILD group, serum MMP-7 levels >5.08 ng/ml were associated with worse overall survival both in univariate (P = 0.017; odds ratio 18.0; 95% CI 1.69, 192.00) and multivariate (P = 0.027; odds ratio 14.60; 95% CI 1.11, 192.00) analyses. Immunohistochemical analysis suggested that MMP-7 was expressed in type II alveolar epithelial cells adjacent to the fibrotic lesions. CONCLUSION: Serum MMP-7 levels were higher in anti-ARS antibody-positive PM/DM-ILD patients, while higher serum MMP-7 levels among anti-MDA5 antibody-positive PM/DM-ILD patients were associated with a worse prognosis. Fibrotic processes may be associated with the elevation of serum MMP-7 levels.
引用
- Nakatsuka Y, Handa T, Nakashima R, et al. Serum matrix metalloproteinase levels in polymyositis/dermatomyositis patients with interstitial lung disease. Rheumatology (Oxford). 2019. PMID: 30851107. doi:10.1093/rheumatology/kez065
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。